Atopic Dermatitis (AD)
70
18
23
28
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.4%
1 terminated out of 70 trials
96.6%
+10.0% vs benchmark
21%
15 trials in Phase 3/4
21%
6 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 28 completed trials
Clinical Trials (70)
Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
A Phase 1 Study of GS101 Injection
Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis
Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
A Pilot Study on the Efficacy of 2% Cholesterol Cream in Preventing Transepidermal Water Loss and Clinical Symptoms in Mild to Moderate Atopic Dermatitis
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis